News

ARC CEO Named Representative of Patient Engagement Collaborative
To strengthen patient involvement, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced the launch of the Patient Engagement Collaborative (PEC). (more…)
Read More
Survey
Hereditary ATTR Patient and Caregiver Treatment Survey
ARC has designed a survey to find out what matters most to patients and their caregivers about treatments for hereditary transthyretin amyloidosis (hATTR).  (more…)
Read More
ICER Report
ARC Provides Vital Feedback for Evaluation of New hATTR Treatments
The Institute of Clinical and Economic Review (ICER), is an independent organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments. (more…)
Read More
Cherry Blossoms at ISA
Report from the 2018 International Symposium on Amyloidosis
This past month, ARC CEO Isabelle Lousada headed to the International Symposium on Amyloidosis (ISA) in Kumamoto, Japan. (more…)
Read More
Clinical Resources APP
ARC Launches Version Two of Powerful Amyloidosis Diagnostic App
A recent ARC survey showed that patients typically see four or more physicians before getting accurately diagnosed, and often those who were misdiagnosed were receiving treatment for their misdiagnosis. The Clinical Resources App was developed to provide healthcare professionals with...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
22 (G1) FORTH STREET, EDINBURGH, UK EH1 3LH | +44 (0) 131 550 3866
arc@arci.org

ARC is a 501(c)(3) nonprofit organization